Nuwellis (NASDAQ:NUWE – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at Roth Mkm in a note issued to investors on Tuesday, Benzinga reports. They presently have a $17.00 price target on the stock.
Separately, Roth Capital raised shares of Nuwellis to a “strong-buy” rating in a research report on Monday, July 29th.
Read Our Latest Analysis on NUWE
Nuwellis Trading Down 23.0 %
Nuwellis Company Profile
Nuwellis, Inc, a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics.
Read More
- Five stocks we like better than Nuwellis
- What is the Dow Jones Industrial Average (DJIA)?
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- How to Capture the Benefits of Dividend Increases
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- 3 Warren Buffett Stocks to Buy Now
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.